Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2024-06-18 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
Successful US FDA Inspection at Patalganga Site with Zero Observations
Regulatory Filings
2024-06-18 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the listing departments of stock exchanges, announcing the successful completion of a US FDA inspection at the company's manufacturing site with zero observations. It is a regulatory compliance update rather than a financial report or detailed corporate filing. The document is short (3772 characters) and serves as an announcement of a regulatory event, not a report or detailed filing. It does not contain financial data, management discussion, voting results, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-06-18 English
Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the listing departments of stock exchanges, announcing the successful completion of a US FDA inspection at the company's manufacturing site with zero observations. It is a regulatory announcement about compliance and inspection results, not a financial report, earnings release, or management discussion. The document is relatively short (3772 characters) and serves as an informational update to regulators and investors. It does not contain financial data, voting results, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-06-18 English
Annual Secretarial Compliance Report for the F.Y. ended 31st March, 2024
Regulatory Filings
2024-05-30 English
Pursuant to regulation 7(3) of SEBI PIT Regulations, please find enclosed herewith dated 17th May 2024 in Form D as received from SBICAP trustee Company Limited.
Regulatory Filings
2024-05-17 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBICAP Trustee Company Ltd
Regulatory Filings
2024-05-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.